Sclerostin: A novel player regulating bone mass in inflammation?

European Journal of Inflammation

Volumn 11, Issue 2, 2013, Pages 345-352

  Albisetti, Walter ^a   Giarratana, L S ^a   Vigano C ^b   Castiglioni, S ^c   Maier, J A ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b A MANZONI HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Bone loss; Inflammation; Sclerostin; Wnt

Indexed keywords

BETA CATENIN; CASEIN KINASE IALPHA; GLYCOGEN SYNTHASE KINASE 3; INTERLEUKIN 8; PROSTAGLANDIN E1; RANTES; SCLEROSTIN; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN;

ANKYLOSING SPONDYLITIS; ARTHRITIS; BONE DISEASE; BONE INFLAMMATION; BONE INJURY; BONE MASS; BONE TURNOVER; CARTILAGE CELL; CHRONIC OBSTRUCTIVE LUNG DISEASE; FIBROBLAST; FRACTURE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KNEE ARTHROPLASTY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSSIFICATION; OSTEOARTHRITIS; OSTEOBLAST; OSTEOLYSIS; PROTEIN LOCALIZATION; REVIEW; SYNOVIUM; WNT SIGNALING PATHWAY;

EID: 84884341266     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X1301100204     Document Type: Review

References (39)

1. Moester MJC, Papapoulos SE, Löwik CWGM, van Bezooijen RL. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 2010; 87:99-107.
2. Li C, Ominsky MS, Tan HL, et al. Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene. Bone 2011; 49(6):1178-85.
3. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001; 10:537-43. (Pubitemid 32184286)
4. Robling AG, Niziolek PJ, Baldridge LA, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008; 283(9):5866-75.
5. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127:469-80.
6. Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007; 148(6):2635-43. (Pubitemid 46984775)
7. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005; 280:19883-87. (Pubitemid 41379516)
8. Leupin O, Halleux C, Morvan F, Hu S, Lu C, Bauer A, Kneissel M. LRP4 is a novel osteoblast and osteocyte expressed specific facilitator of SOST-mediated inhibition of in vitro bone formation. J Bon Miner Res 2009; 24:S1.
9. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CWGM, Reeve J. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005; 19:1842-1844. (Pubitemid 41598769)
10. Baker-LePain JC, Nakamura MC, Lane NE. Effects of inflammation on bone: an update. Curr Opin Rheumatol 2011; 23(4):389-95.
11. George SJ. Wnt pathway: a new role in regulation of inflammation. Arterioscler Thromb Vasc Biol 2008; 28(3):400-2.
12. Redlich K, Görtz B, Hayer S, et al. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol 2004; 164(2):543-55. (Pubitemid 38364670)
13. Lin CL, Moniz C, Chambers TJ, Chow JW. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology 1996; 111:1263-71. (Pubitemid 26362251)
14. Agrawal M, Arora S, Li J, Rahmani R, Sun L, Steinlauf AF, Mechanick JI, Zaidi M. Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep 2011; 9(4):251-7.
15. Graat-Verboom L, Smeenk FW, van den Borne BE, Spruit MA, Donkers-van Rossum AB, Aarts RP, Wouters EF. Risk factors for osteoporosis in Caucasian patients with moderate chronic obstructive pulmonary disease: a case control study. Bone 2012; 50(6):1234-9.
16. Yoshihara A, Seida Y, Hanada N, Miyazaki H. A longitudinal study of the relationship between periodontal disease and bone mineral density in community-dwelling older adults. J Clin Periodontol 2004; 31(8):680-4. (Pubitemid 39092232)
17. Atkins GJ, Kostakis P, Pan B, Farrugia A, Gronthos S, Evdokiou A, Harrison K, Findlay DM, Zannettino AC. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 2003; 18(6):1088-98. (Pubitemid 37294947)
18. Vincent C, Findlay DM, Welldon KJ, et al. Proinflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNF-α induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 2009; 24:1434-49.
19. Chicheportiche Y, Chicheportiche R, Sizing I, Thompson J, Benjamin CB, Ambrose C, Dayer JM. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 2002; 4(2):126-33. (Pubitemid 34257346)
20. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102(2):274-82. (Pubitemid 28335186)
21. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999; 140(10):4382-9. (Pubitemid 30666099)
22. Hayashi K, Yamaguchi T, Yano S, et al. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 2009; 379:261-66.
23. Yun SI, Yoon HY, Jeong SY, Chung YS. Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3beta. J Bone Miner Metab 2009; 27(2):140-8.
24. Yao W, Cheng Z, Pham A, Busse C, Zimmerman EA, Ritchie RO, Lane NE. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Reum 2008; 58:3485-97.
25. Marenzana M, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A, Robinson MK. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum 2001; 63:2385-95.
26. van Lierop AH, van der Eerden AW, Hamdy NA, Hermus AR, den Heijer M, Papapoulos SE. Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J Clin Endocrinol Metab 2012; 97(10):E1953-7.
27. Dean DB, Watson JT, Jin W, Peters C, Enders JT, Chen A, Moed BR, Zhang Z. Distinct functionalities of bone morphogenetic protein antagonists during fracture healing in mice. J Anat 2010; 216(5):625-30.
28. Caetano-Lopes J, Lopes A, Rodrigues A, et al. Upregulation of inflammatory genes and downregulation of sclerostin gene expression are key elements in the early phase of fragility fracture healing. PLoS One 2011; 6(2):e16947.
29. Sarahrudi K, Thomas A, Albrecht C, Aharinejad S. Strongly enhanced levels of sclerostin during human fracture healing. J Orthop Res 2012; 30(10):1549-55.
30. Ominsky MS, Li C, Li X, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 2011; 26(5):1012-21.
31. Wehmeyer C, Stratis A, Pap T, et al. The role of the WNT inhibitor sclerostin in rheumatoid arthritis. Ann Rheum Dis 2010; 69:A1-A76.
32. Appel H, Ruiz-Heiland G, Listing J, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009; 60:3257-62.
33. Felson DT. Developments in the clinical understanding of osteoarthritis. Arthritis Res Ther 2009; 11:203.
34. Chan BY, Fuller ES, Russell AK, et al. Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis. Osteoarthritis Cartilage 2011; 19(7):874-85.
35. Eddleston A, Marenzana M, Moore AR, Stephens P, Muzylak M, Marshall D, Robinson MK. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 2009; 24:1662-71.
36. Gennari L, Merlotti D, Valenti R, et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 2012; 97(5):1737-44.
37. Brooks-Worrell B, Palmer JP. Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clin Exp Immunol 2012; 167(1):40-46.
38. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 2011; 6(10):e25900.
39. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011; 26(1):19-26.